Prof Sanjay Patel
MBBS (Hons 1), PhD, FRACP, FCSANZVisit specialist website
Languages: English, Hindi
Areas of Interest
- Complex coronary intervention
- Structural heart interventions
- Renal artery denervation to treat resistant hypertension
Mater Hospital, North Sydney, NSW
Auburn Cardiology Centre
37 Norval Street
Auburn NSW 2144
T: 02 9646 4044
Sanjay PATEL is co-Director of Auburn Cardiology, a Senior Staff Interventional Cardiologist and Director of the Cardiac Catheterisation Laboratories at Royal Prince Alfred Hospital, Clinical Professor at the Sydney Medical School and NHMRC Clinical Trials Centre, and Head of the Coronary Diseases Group at the Heart Research Institute.
He has more than 13 years of experience and expertise in
- Complex coronary intervention, including intra-coronary imaging and physiology assessments
- Structural heart interventions, including transcatheter aortic valve implantation (TAVI), aortic and mitral valvuloplasty, PFO/ASD closure, left atrial appendage closure, prosthetic perileak closure
- Renal artery denervation to treat resistant hypertension. He is Internationally recognised in this field, with numerous invited speaker opportunities.
He has also established a CT coronary angiography co-reporting service at Royal Prince Alfred Hospital and iMED (Newtown) and currently holds level A CT certification.
He was awarded his MBBS (Hons 1) from the University of Sydney in 2000; completed his advanced cardiology training at Royal Prince Alfred Hospital in 2006; and his PhD in 2009, supported by a NHF postgraduate research scholarship. He then undertook postdoctoral studies at Stanford University, whilst simultaneously training in interventional cardiology at Stanford University Medical Centre (2009-2010), supported by an NHMRC CJ Martin Overseas Fellowship Grant.
As a cardiovascular researcher, he has published over 100 research papers and leads a program which aims to develop novel therapies to target atherosclerosis and its consequences, specifically targeting the inflammation that drives coronary plaque instability.
This program has attracted over $13 million in peer-reviewed research funding. He currently co-leads multiple NHMRC-funded international trials of colchicine in heart attack, stroke and long Covid-19 patients.